Antiangiogenic gene therapy offers an attractive approach to the treatment of a variety of malignancies, including those of the hematological system. However, evaluation of this approach has been hampered by the lack of appropriate animal models. We have recently produced transgenic mice expressing P230 bcr/abl that develop myeloproliferative disease (MPD) closely resembling human chronic myelogenous leukemia. Using this MPD murine model, we examined the feasibility of systemic antiangiogenic gene therapy for hematological malignancy. An adenoviral vector containing the secretable endostatin gene was injected into the right quadriceps muscle of the MPD mice. The increased endostatin level was detected for at least 6 months. Hematological parameters including platelet counts, granulocyte counts, and the hemoglobin concentration were improved by this gene therapy. Infiltration of megakaryocytes was also significantly inhibited in treated MPD mice. Reduction of the microvessel density was confirmed by histological examination. These results demonstrated, for the first time, that antiangiogenic gene therapy is effective to inhibit leukemogenesis caused by expression of the chimeric bcr/abl gene. Gene Therapy (2005) 12, 541-545.
A number of strategies for cancer gene therapy have been developed, but no definitive clinical efficacy has yet been demonstrated. 1 Targeted gene therapy of cancer cells using the suppressor oncogenes or the suicide genes has been hampered by the insufficient efficiency of current gene transfer technologies. 2, 3 Since angiogenesis is essential for both tumor growth and metastasis, antiangiogenic therapy may be an attractive new approach. [4] [5] [6] Both local and systemic expression of antiangiogenic proteins such as angiostatin 7, 8 and endostatin 9, 10 have been attempted to treat various solid tumors to induce tumor dormancy.
Recent studies have suggested that the progression of hematological malignancies also relies on angiogenesis. 11 An increase in microvessel density in bone marrow (BM) specimens has been reported in leukemia patients. 12 Elevated levels of angiogenic factors such as basic fibroblast growth factor and vascular endothelial growth factor (VEGF) have been identified and are thought to be correlated with survival. 13, 14 Therefore, systemic antiangiogenic therapy is likely a promising therapy for hematological malignancies. However, the results of mouse experiments are controversial. Scappaticci et al 15 demonstrated synergistic antitumor activity and enhanced survival of mice bearing L1210 leukemic cells transduced with retroviral vectors expressing angiostatin and endostatin. In contrast, Eisterer et al 16 reported that high levels of serum endostatin secreted from retrovirus transduced BM cells did not alter the growth of transplanted human leukemic cells. The reasons for this discrepancy are not known. One potential problem in these studies is the use of mice transplanted with leukemic cells. Since the development of leukemia from transplanted cells is different from the natural course of leukemogenesis, it should be important to establish a transgenic (tg) animal model in which leukemia develops from endogenous cells under the normal immunological surveillance.
We have recently succeeded in the generation of tg mice expressing P230 bcr/abl, which had leukemogenic properties and induced myeloproliferative disease (MPD). 17 The progression of the disease in this murine model is similar to that of human neutrophilic myelogenous leukemia or chronic myelogenous leukemia with thrombocytosis. Reports have shown that BM microvessel density and serum VEGF are important for the development and prognosis of MPD.
18 P230 bcr-abl has been associated with an indolent MPD as a distinct clinical entity. 19 Thus, angiogenesis may be a critical step in MPD in tg mice expressing P230 bcr-abl. In the present study, we examined the feasibility of antiangiogenic gene therapy for hematological malignancies using this MPD murine model. Since it is difficult to transduce all cancer cells, especially in hematological malignancies, systemic gene therapy appears to be preferable for the inhibition of tumor growth and metastases. Therefore, to obtain systemic expression of antiangiogenic protein, the recombinant adenovirus (Ad) vectors containing the secretable mouse endostatin driven by the CMV promoter (Ad-E; Invivo Gen, San Diego, CA, USA) were injected into the left quadriceps muscle of the 13-to 15-month-old MPD mice.
First, to analyze the duration of sustained expression of endostatin in Ad-E-injected MPD mice, the Ad-E (5 Â 10 8 PFU) was injected into the right quadriceps muscle of the 13-to 15-month-old MPD mice and the concentration of serum endostatin was measured for 2-24 weeks using a enzyme-linked immunosorbent assay (ELISA) kit (ACCUCYTE murine endostatin; CytImmune Sciences, College Park, MD, USA). The background level of serum endostatin in control Ad vector expressing GFP (Ad-G)-injected mice was 56.076.0 ng/ ml, while injection of Ad-E increased the serum endostatin for at least 6 months ( Figure 1 ). The concentration of serum endostatin peaked in the 4th week after injection (320720.5 ng/ml). At 6 months after the injection, serum endostatin was still significantly higher than the control value (86.2710.1 versus 51.872.6 ng/ml, Po0.05).
Since the MPD phenotype developed between 13 and 15 months after birth and the disease progress slowly, we analyzed the effect of systemic expression of endostatin 6 months after Ad-E injection. The results of peripheral blood (PB) examination at 6 months after Ad vector injection are presented in Table 1 . MPD mice were characterized by a decreased concentration of hemoglobin and increased numbers of platelets and granulocytes. Compared to the control, MPD mice injected with Ad-G, injection of Ad-E showed significantly improved hemoglobin concentration (14.070.84 versus 12.670.85 ng/ml, Po0.01), platelet count (98736 versus 144738, Po0.05), and granulocyte count (10217645 versus 36327473, Po0.05). Since huge splenomegaly was detected in MPD mice, we also analyzed the effect of endostatin on splenomegaly (Figure 2a and b) . The longitudinal section area of the spleen was significantly reduced in Ad-Einjected MPD mice compared to Ad-G-injected mice (38.5713.4 versus 86.0724.5 mm 2 , Po0.05, n ¼ 9). Histological examination showed that infiltration of megakaryocytes in the spleen and the BM was significantly inhibited in mice injected with Ad-E (Figure 2c and d  and Table 1) .
To confirm the mechanism of antiangiogenic gene therapy, we attempted to measure the microvessel density in the BM. Immunological staining with Factor VIII or CD31 did not give clear results because of the strong red color of the BM. However, the microvessels composed of one layer of endothelial cells were morphologically distinguishable from other cells in hematoxylin and eosin (H&E)-stained sections (Figure  3a-d) . Compared with the age-matched wild-type mice, the number of microvessels in MPD mice transduced with a control vector (Ad-G) was increased (26. Figure 1 ELISA analysis for serum endostatin in Ad-E-injected mice. The Ad-E or Ad-G (5 Â 10 8 PFU in 50 ml) were injected into the left quadriceps muscle of the 13 to 15-month-old MPD mice (n ¼ 3) and the concentration of serum endostatin was measured for 2-24 weeks using a murine endostatin ELISA kit (ACCUCYTE murine endostatin; CytImmune Sciences, College Park, MD, USA) according to the manufacturer's instructions. Each result represents the mean value and standard deviation of three mice. (Figure 3f ) of microvessels in the femoral BM of Ad-E-injected mice were significantly reduced compared to control Ad-G-injected mice.
Here, we report for the first time that endostatin suppressed proliferative thrombopoiesis and granulopoiesis in MPD in tg mice expressing P230 bcr-abl. The most important point of this work is that we used a tg animal model for analyzing the effect of antiangiogenic gene therapy. Clinical trials of cancer gene therapy have so far been unsuccessful, 2,3 although preclinical animal experiments are highly promising. One reason of the discrepancy between animal models and human patients may be that most of the animal models were generated by inoculation of established cancer cell lines into animals. The mechanisms of development of tumors from transplanted cells are different from the natural course of tumorigenesis. We demonstrated that antiangiogenic gene therapy is effective in treating the tg MPD model, in which leukemia was developed through the common leukemogenic pathway with the bcr/abl mutation. This murine model should prove valuable for the evaluation of other antileukemic therapies as well.
To analyze the effect of endostatin on BM cells obtained from MPD mice in vitro, we examined the proliferation capacity by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using a Cell Titer 96 aqueous nonradioactive cell proliferation assay kit (Promega, Madison, WI, USA), colony-forming units (CFUs) by methylcellulose assay of Ad-E-or Ad-Gtransduced BM cells. However, we did not obtain any differences between Ad-E-and Ad-G-transduced BM cells in either proliferation capacity or the numbers of CFUs (data not shown). To analyze whether the presence of endostatin in Ad-E mice affects primarily the leukemic progenitor cells, we also analyzed expression of bcr-abl gene of CFUs using BM cells obtained from Ad-E-or Ad-G-injected mice by RT-PCR with bcr-abl-specific primer. Expression of bcr-abl gene was detected in all CFUs (n ¼ 20) obtained from both Ad-E-and Ad-G-injected mice (data not shown). These results indicate that endostatin does not influence leukemic cell itself of MPD mice.
In this study, we analyzed the effect of systemic expression of endostatin administrated by single injection of Ad vectors into the muscle. Recently, it was demonstrated that the serum level of endostatin was lower in chronic lymphocytic leukemia patients in advanced stage than in patents in early stage. 20 Therefore, the level of endostatin may have an important role on the progression of hematological malignancies. We think that it is logical to use endostatin for hematological malignancies. Skeletal muscle is an attractive target for gene therapy approaches for the treatment of myopathies and diseases requiring the secretion of proteins through the circulatory system because of its large size, good Antiangiogenic gene therapy of MPD model mouse K Miyake et al capacity for protein synthesis, easy acquisition of sustained expression, and easy accessibility for intramuscular injection. Systemic administration of Ad vectors by intravenous was widely used for many types of gene therapy strategy. [21] [22] [23] However, the toxicity to liver is a big problem of this method. 24, 25 When we checked transaminase (AST, ALT) in our Ad-injected mice, we did not detect the elevation of transaminase in any Ad-injected mice (n ¼ 9). However, using musclespecific promoters or improving vector tropism for skeletal muscle may be useful to obtain safer and more efficient therapy after intramuscular administration of Ad vectors.
To study the utility of antiangiogenic gene therapy, we used Ad vectors, which are useful for transient expression of soluble proteins in muscle. On the other hand, adeno-associated virus (AAV) vectors have produced long-term expression of a therapeutic gene that is either integrated or an episomal vector genome. 26 Moreover, it was reported that AAV-1, AAV-5, and AAV-7 could transduce murine skeletal muscle more efficiently than the more widely used serotype AAV-2. 27, 28 Therefore, these AAV vectors may be more suitable for clinical trials of systemic antiangiogenic therapy targeting skeletal muscle.
An alternative approach for antiangiogenic gene therapy of hematological malignancy is the use of hematopoietic stem cells (HSCs) transduced with integrating vectors such as oncoretroviral or lentiviral vectors. 29 Long-term reconstitution with retroviral HSCs have been attained even in human clinical trials. As transplanted HSCs invade within the extravascular BM space, a high concentration of endostatin could be achieved at the site of malignant cell growth. We are currently attempting to evaluate this approach for longterm therapy of MPD model mice.
We demonstrated that an antiangiogenic strategy is effective to treat MPD of tg model mice. Although a first remission could be often achieved by rigorous chemotherapy programs, reappearance of the malignant cells is still a major concern in the treatment of leukemia. Antiangiogenic gene therapy may offer an important option for the establishment of the long-term anticancer state after remission induction of various hematological malignancies.
